Amgen Inc. (NASDAQ:AMGN) Shares Sold by Curi RMB Capital LLC

Curi RMB Capital LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 15.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,685 shares of the medical research company's stock after selling 7,485 shares during the period. Curi RMB Capital LLC's holdings in Amgen were worth $10,865,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Vanguard Group Inc. boosted its stake in shares of Amgen by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 52,721,795 shares of the medical research company's stock valued at $13,741,409,000 after buying an additional 339,522 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Amgen by 25.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after acquiring an additional 2,672,975 shares during the last quarter. Geode Capital Management LLC grew its holdings in Amgen by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company's stock worth $3,245,881,000 after acquiring an additional 352,143 shares in the last quarter. Capital International Investors increased its position in shares of Amgen by 40.1% in the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock valued at $3,182,843,000 after purchasing an additional 3,495,503 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Amgen in the 4th quarter valued at $1,541,991,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of NASDAQ:AMGN traded up $1.94 during trading on Thursday, hitting $279.84. 2,259,588 shares of the stock were exchanged, compared to its average volume of 2,788,099. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a market cap of $150.46 billion, a PE ratio of 37.06, a P/E/G ratio of 2.63 and a beta of 0.59. The company has a fifty day moving average price of $301.98 and a two-hundred day moving average price of $293.34. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.40%. The ex-dividend date is Friday, May 16th. Amgen's payout ratio is currently 126.09%.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent analyst reports. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a report on Thursday, April 17th. Piper Sandler Companies reiterated an "overweight" rating and issued a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Bank of America boosted their target price on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research note on Wednesday, March 5th. Cantor Fitzgerald initiated coverage on shares of Amgen in a report on Tuesday. They set a "neutral" rating and a $305.00 price objective on the stock. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $324.00 price target on shares of Amgen in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $310.57.

Insiders Place Their Bets

In related news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company's stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,341 shares of company stock worth $20,644,335. Insiders own 0.69% of the company's stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.